StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Wednesday. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Up 2.8 %

NYSE ENZ opened at $0.73 on Wednesday. Enzo Biochem has a 12 month low of $0.68 and a 12 month high of $1.50. The company’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.09.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 15th were issued a dividend of $0.10 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 54.95%.

Institutional Investors Weigh In On Enzo Biochem

Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd lifted its stake in Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares in the last quarter. BBR Partners LLC acquired a new position in shares of Enzo Biochem in the 3rd quarter valued at about $112,000. Geode Capital Management LLC lifted its position in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.